{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:55:05Z","timestamp":1790744105787,"version":"4.1.0"},"reference-count":146,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100023015","name":"Advanced Research Projects Agency for Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100023015","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ymthe.2026.08.047","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:45:45Z","timestamp":1788417945000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Protein-based masks to unlock conditional activation of therapeutics"],"prefix":"10.1016","author":[{"given":"Nithya M.","family":"Badarinath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6110-2938","authenticated-orcid":false,"given":"John","family":"Blazeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2026.08.047_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1208\/s12248-023-00873-8","article-title":"Therapeutic Fusion Proteins","volume":"26","author":"Marsh","year":"2023","journal-title":"AAPS J."},{"key":"10.1016\/j.ymthe.2026.08.047_bib2","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.cell.2020.02.001","article-title":"Targeting Strategies for Tissue-Specific Drug Delivery","volume":"181","author":"Zhao","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2026.08.047_bib3","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s40264-015-0285-9","article-title":"Chimeric fusion proteins used for therapy: indications, mechanisms, and safety","volume":"38","author":"Baldo","year":"2015","journal-title":"Drug Saf."},{"key":"10.1016\/j.ymthe.2026.08.047_bib4","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrd3003","article-title":"The safety and side effects of monoclonal antibodies","volume":"9","author":"Hansel","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2026.08.047_bib5","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2026.08.047_bib6","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","article-title":"Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours","volume":"20","author":"Flugel","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2026.08.047_bib7","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13054-017-1678-1","article-title":"New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management","volume":"21","author":"Kroschinsky","year":"2017","journal-title":"Crit. Care"},{"key":"10.1016\/j.ymthe.2026.08.047_bib8","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1021\/jacsau.2c00654","article-title":"Strategies for Conditional Regulation of Proteins","volume":"3","author":"Nadendla","year":"2023","journal-title":"JACS Au"},{"key":"10.1016\/j.ymthe.2026.08.047_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.copbio.2022.102809","article-title":"Engineering antibodies for conditional activity in the solid tumor microenvironment","volume":"78","author":"Liu","year":"2022","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.ymthe.2026.08.047_bib10","doi-asserted-by":"crossref","DOI":"10.1038\/srep18950","article-title":"Design of chimeric antigen receptors with integrated controllable transient functions","volume":"6","author":"Juillerat","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2026.08.047_bib11","doi-asserted-by":"crossref","DOI":"10.1126\/science.aab4077","article-title":"Remote control of therapeutic T cells through a small molecule-gated chimeric receptor","volume":"350","author":"Wu","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2026.08.047_bib12","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.ccell.2022.08.008","article-title":"High-performance multiplex drug-gated CAR circuits","volume":"40","author":"Li","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ymthe.2026.08.047_bib13","doi-asserted-by":"crossref","first-page":"138","DOI":"10.4161\/19420862.2014.985993","article-title":"A generic approach to engineer antibody pH-switches using combinatorial histidine scanning libraries and yeast display","volume":"7","author":"Schr\u00f6ter","year":"2015","journal-title":"MAbs"},{"key":"10.1016\/j.ymthe.2026.08.047_bib14","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/s41592-019-0592-7","article-title":"Optogenetic activation of intracellular antibodies for direct modulation of endogenous proteins","volume":"16","author":"Yu","year":"2019","journal-title":"Nat. Methods"},{"key":"10.1016\/j.ymthe.2026.08.047_bib15","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41592-020-0746-7","article-title":"Chemogenetic Control of Nanobodies","volume":"17","author":"Farrants","year":"2020","journal-title":"Nat. Methods"},{"key":"10.1016\/j.ymthe.2026.08.047_bib16","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1080\/19420862.2016.1277302","article-title":"A strategy to identify linker-based modules for the allosteric regulation of antibody-antigen binding affinities of different scFvs","volume":"9","author":"Kellmann","year":"2017","journal-title":"MAbs"},{"key":"10.1016\/j.ymthe.2026.08.047_bib17","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1158\/2159-8290.CD-20-0328","article-title":"Antibody to CD137 Activated by Extracellular Adenosine Triphosphate Is Tumor Selective and Broadly Effective In Vivo without Systemic Immune Activation","volume":"11","author":"Kamata-Sakurai","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ymthe.2026.08.047_bib18","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1038\/ncomms5388","article-title":"Creation of a gated antibody as a conditionally functional synthetic protein","volume":"5","author":"Gunnoo","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.08.047_bib19","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s10875-012-9689-9","article-title":"Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling","volume":"32","author":"Wilkie","year":"2012","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.ymthe.2026.08.047_bib20","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1126\/science.aba6527","article-title":"Designed protein logic to target cells with precise combinations of surface antigens","volume":"369","author":"Lajoie","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2026.08.047_bib21","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2026.08.047_bib22","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12929-020-00652-z","article-title":"Ab locks for improving the selectivity and safety of antibody drugs","volume":"27","author":"Lin","year":"2020","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.ymthe.2026.08.047_bib23","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2022.2095701","article-title":"Mechanistic insights into the rational design of masked antibodies","volume":"14","author":"Orozco","year":"2022","journal-title":"MAbs"},{"key":"10.1016\/j.ymthe.2026.08.047_bib24","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1021\/acscentsci.0c01448","article-title":"The Masking Game: Design of Activatable Antibodies and Mimetics for Selective Therapeutics and Cell Control","volume":"7","author":"Lucchi","year":"2021","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.ymthe.2026.08.047_bib25","doi-asserted-by":"crossref","first-page":"17986","DOI":"10.1002\/anie.201908655","article-title":"Site-Specific Encoding of Photoactivity in Antibodies Enables Light-Mediated Antibody-Antigen Binding on Live Cells","volume":"58","author":"Bridge","year":"2019","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ymthe.2026.08.047_bib26","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1021\/acs.molpharmaceut.9b00393","article-title":"Polymer Masked-Unmasked Protein Therapy: Identification of the Active Species after Amylase Activation of Dextrin-Colistin Conjugates","volume":"16","author":"Varache","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ymthe.2026.08.047_bib27","doi-asserted-by":"crossref","first-page":"6345","DOI":"10.1038\/s41467-023-41894-3","article-title":"Structure-based design of a phosphotyrosine-masked covalent ligand targeting the E3 ligase SOCS2","volume":"14","author":"Ramachandran","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.08.047_bib28","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2019.1682866","article-title":"Structure-based engineering of pH-dependent antibody binding for selective targeting of solid-tumor microenvironment","volume":"12","author":"Sulea","year":"2020","journal-title":"MAbs"},{"key":"10.1016\/j.ymthe.2026.08.047_bib29","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.cell.2010.03.015","article-title":"Matrix metalloproteinases: regulators of the tumor microenvironment","volume":"141","author":"Kessenbrock","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2026.08.047_bib30","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1158\/0008-5472.CAN-12-2796","article-title":"Acidity generated by the tumor microenvironment drives local invasion","volume":"73","author":"Estrella","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2026.08.047_bib31","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1111\/febs.15227","article-title":"Protease-activated prodrugs: strategies, challenges, and future directions","volume":"287","author":"Poreba","year":"2020","journal-title":"FEBS J."},{"key":"10.1016\/j.ymthe.2026.08.047_bib32","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1002\/bit.27111","article-title":"Tunable modulation of antibody-antigen interaction by protease cleavage of protein M","volume":"116","author":"Kim","year":"2019","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.ymthe.2026.08.047_bib33","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/ardp.200700025","article-title":"Synthesis, cleavage profile, and antitumor efficacy of an albumin-binding prodrug of methotrexate that is cleaved by plasmin and cathepsin B","volume":"340","author":"Warnecke","year":"2007","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.ymthe.2026.08.047_bib34","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1074\/mcp.O112.025486","article-title":"Masked selection: a straightforward and flexible approach for the selection of binders against specific epitopes and differentially expressed proteins by phage display","volume":"13","author":"Even-Desrumeaux","year":"2014","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.ymthe.2026.08.047_bib35","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ijbiomac.2021.04.032","article-title":"An anti-HER2 nanobody binds to its antigen HER2 via two independent paratopes","volume":"182","author":"Ubbiali","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ymthe.2026.08.047_bib36","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.4161\/cbt.8.22.9765","article-title":"Design and development of masked therapeutic antibodies to limit off-target effects: application to anti-EGFR antibodies","volume":"8","author":"Donaldson","year":"2009","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.ymthe.2026.08.047_bib37","doi-asserted-by":"crossref","DOI":"10.1093\/protein\/gzaf006","article-title":"A facile yeast-display approach for antibody mask discovery","volume":"38","author":"Badarinath","year":"2025","journal-title":"Protein Eng. Des. Sel."},{"key":"10.1016\/j.ymthe.2026.08.047_bib38","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/s41551-022-00888-0","article-title":"Masking the immunotoxicity of interleukin-12 by fusing it with a domain of its receptor via a tumour-protease-cleavable linker","volume":"6","author":"Mansurov","year":"2022","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.ymthe.2026.08.047_bib39","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1074\/jbc.M411047200","article-title":"A novel peptide isolated from a phage display peptide library with trastuzumab can mimic antigen epitope of HER-2","volume":"280","author":"Jiang","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymthe.2026.08.047_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fbinf.2024.1295972","article-title":"Computational identification of antibody-binding epitopes from mimotope datasets","volume":"4","author":"Li","year":"2024","journal-title":"Front. Bioinform."},{"key":"10.1016\/j.ymthe.2026.08.047_bib41","doi-asserted-by":"crossref","first-page":"45495","DOI":"10.1021\/jacs.5c16108","article-title":"De Novo Design of Peptide Masks Enables Rapid Generation of Conditionally-Active Miniprotein Binders","volume":"147","author":"Escobar-Rosales","year":"2025","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ymthe.2026.08.047_bib42","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.jconrel.2012.05.035","article-title":"Site-specific targeting of antibody activity in vivo mediated by disease-associated proteases","volume":"161","author":"Erster","year":"2012","journal-title":"J. Control Release"},{"key":"10.1016\/j.ymthe.2026.08.047_bib43","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/nature19946","article-title":"The coming of age of de novo protein design","volume":"537","author":"Huang","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.08.047_bib44","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s43018-023-00536-9","article-title":"Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumors","volume":"4","author":"Cattaruzza","year":"2023","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.ymthe.2026.08.047_bib45","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41587-019-0135-x","article-title":"A coiled-coil masking domain for selective activation of therapeutic antibodies","volume":"37","author":"Trang","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2026.08.047_bib46","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1093\/protein\/gzs064","article-title":"Bispecific antibody derivatives with restricted binding functionalities that are activated by proteolytic processing","volume":"25","author":"Metz","year":"2012","journal-title":"Protein Eng. Des. Sel."},{"key":"10.1016\/j.ymthe.2026.08.047_bib47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3000286","article-title":"Specific activation of pro-Infliximab enhances selectivity and safety of rheumatoid arthritis therapy","volume":"17","author":"Lu","year":"2019","journal-title":"Plos Biol."},{"key":"10.1016\/j.ymthe.2026.08.047_bib48","article-title":"Selective antibody activation through protease-activated pro-antibodies that mask binding sites with inhibitory domains","volume":"7","author":"Chen","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2026.08.047_bib49","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2024.2443538","article-title":"Antibodies to watch in 2025","volume":"17","author":"Crescioli","year":"2025","journal-title":"MAbs"},{"key":"10.1016\/j.ymthe.2026.08.047_bib50","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1080\/19420862.2015.1008352","article-title":"Generation and characterization of a target-selectively activated antibody against epidermal growth factor receptor with enhanced anti-tumor potency","volume":"7","author":"Yang","year":"2015","journal-title":"MAbs"},{"key":"10.1016\/j.ymthe.2026.08.047_bib51","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1080\/19420862.2015.1127491","article-title":"Preclinical studies of a Pro-antibody-drug conjugate designed to selectively target EGFR-overexpressing tumors with improved therapeutic efficacy","volume":"8","author":"Yang","year":"2016","journal-title":"MAbs"},{"key":"10.1016\/j.ymthe.2026.08.047_bib52","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2024.2373325","article-title":"Engineering a tumor-selective prodrug T-cell engager bispecific antibody for safer immunotherapy","volume":"16","author":"McCue","year":"2024","journal-title":"MAbs"},{"key":"10.1016\/j.ymthe.2026.08.047_bib53","article-title":"Mask peptides and masked anti-ptk7 antibodies comprising such","author":"Sagert","year":"2021","journal-title":"US Patent Application US20230181750A1"},{"key":"10.1016\/j.ymthe.2026.08.047_bib54","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1158\/2326-6066.CIR-21-0031","article-title":"Conditional PD-1\/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Anti-PD-1\/PD-L1 Agents","volume":"9","author":"Assi","year":"2021","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ymthe.2026.08.047_bib55","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006682","article-title":"Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index","volume":"5","author":"Desnoyers","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2026.08.047_bib56","doi-asserted-by":"crossref","first-page":"4288","DOI":"10.1158\/0008-5472.CAN-21-2483","article-title":"A Probody T Cell-Engaging Bispecific Antibody Targeting EGFR and CD3 Inhibits Colon Cancer Growth with Limited Toxicity","volume":"82","author":"Boustany","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2026.08.047_bib57","doi-asserted-by":"crossref","DOI":"10.1002\/biot.202400432","article-title":"A Competition-Based Strategy for the Isolation of an Anti-Idiotypic Blocking Module and Fine-Tuning for Conditional Activation of a Therapeutic Antibody","volume":"19","author":"Habermann","year":"2024","journal-title":"Biotechnol. J."},{"key":"10.1016\/j.ymthe.2026.08.047_bib58","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1038\/s41467-020-16838-w","article-title":"Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody","volume":"11","author":"Geiger","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.08.047_bib59","article-title":"Protease cleavable prodrugs","author":"Bosshart","year":"2022","journal-title":"United States Patent Application US20240156980A1"},{"key":"10.1016\/j.ymthe.2026.08.047_bib60","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/j.drudis.2022.03.011","article-title":"Exploiting protease activation for therapy","volume":"27","author":"Bleuez","year":"2022","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ymthe.2026.08.047_bib61","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/978-1-0716-1186-9_18","article-title":"Recombinant Anti-idiotypic Antibodies in Ligand Binding Assays for Antibody Drug Development","volume":"2261","author":"Harth","year":"2021","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ymthe.2026.08.047_bib62","first-page":"373","article-title":"Towards a network theory of the immune system","volume":"125C","author":"Jerne","year":"1974","journal-title":"Ann. Immunol."},{"key":"10.1016\/j.ymthe.2026.08.047_bib63","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.drudis.2008.04.013","article-title":"DARPins: a new generation of protein therapeutics","volume":"13","author":"Stumpp","year":"2008","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ymthe.2026.08.047_bib64","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1021\/acs.molpharmaceut.6b00280","article-title":"In-Depth Characterization of a Pro-Antibody-Drug Conjugate by LC-MS","volume":"13","author":"Liu","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ymthe.2026.08.047_bib65","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.nbt.2023.07.004","article-title":"Incorporation of a repeated polypeptide sequence in therapeutic antibodies as a universal masking procedure: A case study of T cell-engaging bispecific antibodies","volume":"77","author":"Maejima","year":"2023","journal-title":"N. Biotechnol."},{"key":"10.1016\/j.ymthe.2026.08.047_bib66","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1002\/art.39232","article-title":"Rational design of antirheumatic prodrugs specific for sites of inflammation","volume":"67","author":"Onuoha","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.ymthe.2026.08.047_bib67","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1172\/JCI123391","article-title":"Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity","volume":"129","author":"Pai","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2026.08.047_bib68","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1039\/c3sc22033h","article-title":"Reversible blocking of antibodies using bivalent peptide\u2013DNA conjugates allows protease-activatable targeting","volume":"4","author":"Janssen","year":"2013","journal-title":"Chem. Sci."},{"key":"10.1016\/j.ymthe.2026.08.047_bib69","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1021\/acscentsci.9b00964","article-title":"Programmable Bivalent Peptide-DNA Locks for pH-Based Control of Antibody Activity","volume":"6","author":"Engelen","year":"2020","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.ymthe.2026.08.047_bib70","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/nbt.1588","article-title":"A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner","volume":"27","author":"Schellenberger","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2026.08.047_bib71","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0050630","article-title":"GLP2-2G-XTEN: a pharmaceutical protein with improved serum half-life and efficacy in a rat Crohn's disease model","volume":"7","author":"Alters","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2026.08.047_bib72","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/rheumatology\/keg037","article-title":"Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis","volume":"42","author":"Green","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ymthe.2026.08.047_bib73","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1136\/ard.2003.013243","article-title":"MMP profile in paired serum and synovial fluid samples of patients with rheumatoid arthritis","volume":"63","author":"Tchetverikov","year":"2004","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ymthe.2026.08.047_bib74","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/JLB.2MR0220-549R","article-title":"ICAM-1: A master regulator of cellular responses in inflammation, injury resolution, and tumorigenesis","volume":"108","author":"Bui","year":"2020","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.ymthe.2026.08.047_bib75","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1074\/jbc.M117.809657","article-title":"Prodomain-growth factor swapping in the structure of pro-TGF-beta1","volume":"293","author":"Zhao","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymthe.2026.08.047_bib76","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1107\/S205225251901707X","article-title":"Structural insights into conformational switching in latency-associated peptide between transforming growth factor beta-1 bound and unbound states","volume":"7","author":"Stachowski","year":"2020","journal-title":"IUCrJ"},{"key":"10.1016\/j.ymthe.2026.08.047_bib77","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1084\/jem.175.6.1799","article-title":"Self-peptide released from class II HLA-DR1 exhibits a hydrophobic two-residue contact motif","volume":"175","author":"Kropshofer","year":"1992","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ymthe.2026.08.047_bib78","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/j.1365-2567.2012.03579.x","article-title":"Characterizing the binding motifs of 11 common human HLA-DP and HLA-DQ molecules using NNAlign","volume":"136","author":"Andreatta","year":"2012","journal-title":"Immunology"},{"key":"10.1016\/j.ymthe.2026.08.047_bib79","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1126\/science.1061692","article-title":"Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design","volume":"293","author":"Saphire","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2026.08.047_bib80","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s00018-014-1751-8","article-title":"A new prodrug form of Affibody molecules (pro-Affibody) is selectively activated by cancer-associated proteases","volume":"72","author":"Sandersj\u00f6\u00f6","year":"2015","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ymthe.2026.08.047_bib81","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.nbt.2022.12.002","article-title":"Generation of an anti-idiotypic affibody-based masking domain for conditional activation of EGFR-targeting","volume":"73","author":"Mestre Borras","year":"2023","journal-title":"N. Biotechnol."},{"key":"10.1016\/j.ymthe.2026.08.047_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2025.151660","article-title":"Affibody-based HER2 prodrug shows conditional cytotoxic effect on HER2-positive cancer cells","volume":"758","author":"Westerberg","year":"2025","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ymthe.2026.08.047_bib83","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jconrel.2023.03.046","article-title":"Conditionally activated affibody-based prodrug targeting EGFR demonstrates improved tumour selectivity","volume":"357","author":"Dahlsson Leitao","year":"2023","journal-title":"J. Control Release"},{"key":"10.1016\/j.ymthe.2026.08.047_bib84","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ymthe.2016.10.011","article-title":"Masked Chimeric Antigen Receptor for Tumor-Specific Activation","volume":"25","author":"Han","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.08.047_bib85","article-title":"Masked chimeric antigen receptor specific to tyrosine-protein kinase like 7 (ptk7) and immune cells expressing such","author":"Sagert","year":"2024","journal-title":"United States Patent Application US20240352151A1"},{"key":"10.1016\/j.ymthe.2026.08.047_bib86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-61779-921-1_1","article-title":"Therapeutic proteins","volume":"899","author":"Dimitrov","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ymthe.2026.08.047_bib87","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s40264-014-0226-z","article-title":"Side effects of cytokines approved for therapy","volume":"37","author":"Baldo","year":"2014","journal-title":"Drug Saf."},{"key":"10.1016\/j.ymthe.2026.08.047_bib88","first-page":"123","article-title":"Next-generation cytokines for cancer immunotherapy","volume":"4","author":"Xue","year":"2021","journal-title":"Antib. Ther."},{"key":"10.1016\/j.ymthe.2026.08.047_bib89","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1158\/1535-7163.MCT-20-0457","article-title":"Single-Dose Anti-PD-L1\/IL-15 Fusion Protein KD033 Generates Synergistic Antitumor Immunity with Robust Tumor-Immune Gene Signatures and Memory Responses","volume":"20","author":"Martomo","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ymthe.2026.08.047_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109634","article-title":"Anti-Claudin18.2-IL-21 fusion protein bifunctional molecule has more powerful anti-tumor effect and better safety","volume":"115","author":"Zhou","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ymthe.2026.08.047_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111478","article-title":"Engineered human cytokine\/antibody fusion proteins expand regulatory T cells and confer autoimmune disease protection","volume":"41","author":"VanDyke","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.ymthe.2026.08.047_bib92","doi-asserted-by":"crossref","first-page":"18139","DOI":"10.1074\/jbc.M116.737734","article-title":"Targeted Reconstitution of Cytokine Activity upon Antigen Binding using Split Cytokine Antibody Fusion Proteins","volume":"291","author":"Venetz","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymthe.2026.08.047_bib93","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/s41587-022-01510-z","article-title":"A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy","volume":"41","author":"Quijano-Rubio","year":"2023","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2026.08.047_bib94","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1038\/s41467-021-22980-w","article-title":"A cytokine receptor-masked IL2 prodrug selectively activates tumor-infiltrating lymphocytes for potent antitumor therapy","volume":"12","author":"Hsu","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.08.047_bib95","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1038\/s41422-021-00543-4","article-title":"Tumor-conditional IL-15 pro-cytokine reactivates anti-tumor immunity with limited toxicity","volume":"31","author":"Guo","year":"2021","journal-title":"Cell Res."},{"key":"10.1016\/j.ymthe.2026.08.047_bib96","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1365-2567.2011.03428.x","article-title":"Development of an attenuated interleukin-2 fusion protein that can be activated by tumour-expressed proteases","volume":"133","author":"Puskas","year":"2011","journal-title":"Immunology"},{"key":"10.1016\/j.ymthe.2026.08.047_bib97","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1158\/2326-6066.CIR-21-0831","article-title":"Discovery of a Conditionally Activated IL-2 that Promotes Antitumor Immunity and Induces Tumor Regression","volume":"10","author":"Nirschl","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ymthe.2026.08.047_bib98","article-title":"Masked il-2 cytokines and methods of use thereof","author":"Johnson","year":"2025","journal-title":"United States Patent Application US20250101075A1"},{"key":"10.1016\/j.ymthe.2026.08.047_bib99","doi-asserted-by":"crossref","first-page":"6850","DOI":"10.4049\/jimmunol.212.supp.0864.6850","article-title":"Development of conditionally active IL-10 INDUKINE TM molecules for the treatment of inflammatory bowel disease","volume":"212","author":"Sullivan","year":"2024","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2026.08.047_bib100","article-title":"A PD-1-targeted, receptor-masked IL-2 immunocytokine that engages IL-2Ralpha strengthens T cell-mediated anti-tumor therapies","volume":"5","author":"Wu","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.ymthe.2026.08.047_bib101","article-title":"Next-generation anti-PD-L1\/IL-15 immunocytokine elicits superior antitumor immunity in cold tumors with minimal toxicity","volume":"5","author":"Shi","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.ymthe.2026.08.047_bib102","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.1038\/s41467-021-26112-2","article-title":"Next generation of tumor-activating type I IFN enhances anti-tumor immune responses to overcome therapy resistance","volume":"12","author":"Cao","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.08.047_bib103","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1038\/sj.onc.1205193","article-title":"TNF-Selectokine: a novel prodrug generated for tumor targeting and site-specific activation of tumor necrosis factor","volume":"21","author":"W\u00fcest","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.ymthe.2026.08.047_bib104","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1007\/s00262-006-0162-6","article-title":"Target-selective activation of a TNF prodrug by urokinase-type plasminogen activator (uPA) mediated proteolytic processing at the cell surface","volume":"55","author":"Gerspach","year":"2006","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ymthe.2026.08.047_bib105","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011944","article-title":"Universal Fab-Fc masked cytokine prodrug platform: alphaPD-L1\/IL-15 prodrug activates CD44(+) CD8(+) T cells in tumor-draining lymph nodes to enhance antitumor immunity","volume":"13","author":"Song","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2026.08.047_bib106","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2513720123","article-title":"A modular platform for Sterically Masked Activated Cytokines (SMACks)","volume":"123","author":"Morgenstern","year":"2026","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2026.08.047_bib107","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1073\/pnas.1416159112","article-title":"Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution","volume":"112","author":"Tzeng","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2026.08.047_bib108","article-title":"A targeted masked ImmunoCytokine for CD138 expressing cancers","volume":"11","author":"Trinh","year":"2023","journal-title":"J. ImmunoTher. Cancer"},{"key":"10.1016\/j.ymthe.2026.08.047_bib109","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1158\/1078-0432.CCR-19-1457","article-title":"Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology","volume":"26","author":"Autio","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2026.08.047_bib110","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002447","article-title":"CX-072 (pacmilimab), a Probody ((R)) PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study","volume":"9","author":"Naing","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2026.08.047_bib111","doi-asserted-by":"crossref","first-page":"5325","DOI":"10.1158\/1078-0432.CCR-21-0453","article-title":"First-in-Human Study of the Biodistribution and Pharmacokinetics of 89Zr-CX-072, a Novel Immunopet Tracer Based on an Anti-PD-L1 Probody","volume":"27","author":"Kist de Ruijter","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2026.08.047_bib112","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1158\/1078-0432.CCR-21-3656","article-title":"Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I\/II Trial","volume":"28","author":"Boni","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2026.08.047_bib113","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1158\/1078-0432.CCR-21-0194","article-title":"Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor Malignancies","volume":"27","author":"Johnson","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2026.08.047_bib114","series-title":"Anti-CTLA-4 Probody BMS-986249 Alone or in Combination with Nivolumab in Patients with Advanced Cancers: Initial Phase I Results","author":"Gutierrez","year":"2020"},{"key":"10.1016\/j.ymthe.2026.08.047_bib115","series-title":"CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904","year":"2024"},{"key":"10.1016\/j.ymthe.2026.08.047_bib116","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/j.cell.2026.03.025","article-title":"Mapping intratumor heterogeneity across layers for advancing immunotherapy","volume":"189","author":"Marine","year":"2026","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2026.08.047_bib117","article-title":"Programming T cells for Early Cancer Detection with Customized Protease-Activatable Receptors","author":"Phuengkham","year":"2026","journal-title":"bioRxiv."},{"key":"10.1016\/j.ymthe.2026.08.047_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102978","article-title":"Immunocytokines in cancer treatment: A systematic review","volume":"139","author":"Agliardi","year":"2025","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.ymthe.2026.08.047_bib119","author":"Moser","year":"2024"},{"key":"10.1016\/j.ymthe.2026.08.047_bib120","series-title":"The Tumor-Activated IL-12 Prodrug WTX-330 Expanded and Activated Tumor Infiltrating Lymphocytes and Caused Tumor Regression in Patients with Refractory Solid Tumors: Interim Data from an Ongoing Phase 1 Study","author":"Mahalingam","year":"2024"},{"key":"10.1016\/j.ymthe.2026.08.047_bib121","series-title":"Patients with Advanced Solid Tumors","article-title":"Phase 1\/2 First-in Human Study of XTX202, a Masked, Tumor-Activated IL-2\u03b2\u03b3","author":"Hanna","year":"2024"},{"key":"10.1016\/j.ymthe.2026.08.047_bib122","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1158\/1535-7163.MCT-23-0336","article-title":"XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies","volume":"23","author":"Patel","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ymthe.2026.08.047_bib123","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ymthe.2026.08.047_bib124","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02588-18","article-title":"A Phase 1, Randomized, Single-Ascending-Dose Study To Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S, an Anti-Staphylococcus aureus Thiomab Antibody-Antibiotic Conjugate, in Healthy Volunteers","volume":"63","author":"Peck","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ymthe.2026.08.047_bib125","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1021\/acs.accounts.3c00597","article-title":"Unleashing the Power of Proenzyme Delivery for Targeted Therapeutic Applications Using Biodegradable Lipid Nanoparticles","volume":"57","author":"Zheng","year":"2024","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.ymthe.2026.08.047_bib126","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/imm.12982","article-title":"Characterizing a pH-switch anti-C5 antibody as a tool for human and mouse complement C5 purification and cross-species inhibition of classical and reactive lysis","volume":"155","author":"Zelek","year":"2018","journal-title":"Immunology"},{"key":"10.1016\/j.ymthe.2026.08.047_bib127","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1021\/bi3016668","article-title":"Anti-idiotypic monobodies derived from a fibronectin scaffold","volume":"52","author":"Sullivan","year":"2013","journal-title":"Biochemistry"},{"key":"10.1016\/j.ymthe.2026.08.047_bib128","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ymeth.2012.07.009","article-title":"Anti-idiotypic monobodies for immune response profiling","volume":"58","author":"Sullivan","year":"2012","journal-title":"Methods"},{"key":"10.1016\/j.ymthe.2026.08.047_bib129","doi-asserted-by":"crossref","first-page":"8972","DOI":"10.1038\/s41598-018-27264-w","article-title":"A Versatile Safeguard for Chimeric Antigen Receptor T-Cell Immunotherapies","volume":"8","author":"Valton","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2026.08.047_bib130","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/s41551-025-01470-0","article-title":"Directed evolution-based discovery of ligands for in vivo restimulation of chimeric antigen receptor T cells","volume":"10","author":"Grzywa","year":"2026","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.ymthe.2026.08.047_bib131","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S1359-6446(03)02953-2","article-title":"Minimizing the immunogenicity of protein therapeutics","volume":"9","author":"Chirino","year":"2004","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ymthe.2026.08.047_bib132","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s40259-023-00641-2","article-title":"Reducing Immunogenicity by Design: Approaches to Minimize Immunogenicity of Monoclonal Antibodies","volume":"38","author":"Harris","year":"2024","journal-title":"BioDrugs."},{"key":"10.1016\/j.ymthe.2026.08.047_bib133","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1039\/b904878b","article-title":"Systemic in vivo distribution of activatable cell penetrating peptides is superior to that of cell penetrating peptides","volume":"1","author":"Aguilera","year":"2009","journal-title":"Integr. Biol."},{"key":"10.1016\/j.ymthe.2026.08.047_bib134","doi-asserted-by":"crossref","first-page":"32933","DOI":"10.1021\/jacs.4c06160","article-title":"Conditionally Activatable Chimeras for Tumor-Specific Membrane Protein Degradation","volume":"146","author":"Liu","year":"2024","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ymthe.2026.08.047_bib135","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1146\/annurev-pharmtox-010818-021118","article-title":"Engineered Protein Scaffolds as Next-Generation Therapeutics","volume":"60","author":"Gebauer","year":"2020","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.ymthe.2026.08.047_bib136","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2025.110268","article-title":"Evaluation of AlphaFold modeling for elucidation of nanobody-peptide epitope interactions","volume":"301","author":"Sachdev","year":"2025","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymthe.2026.08.047_bib137","doi-asserted-by":"crossref","DOI":"10.1016\/j.foodchem.2022.133317","article-title":"Rapid and sensitive noncompetitive immunoassay for detection of aflatoxin B1 based on anti-immune complex peptide","volume":"393","author":"Zou","year":"2022","journal-title":"Food Chem."},{"key":"10.1016\/j.ymthe.2026.08.047_bib138","doi-asserted-by":"crossref","DOI":"10.1016\/j.foodchem.2024.142061","article-title":"Mimotope peptides for nanobodies: A nontoxic alternative to ochratoxin A and its application in chemiluminescence immunoassays for analysis of pepper samples","volume":"465","author":"Mao","year":"2025","journal-title":"Food Chem."},{"key":"10.1016\/j.ymthe.2026.08.047_bib139","doi-asserted-by":"crossref","DOI":"10.1016\/j.foodchem.2020.128084","article-title":"Application of phage-display developed antibody and antigen substitutes in immunoassays for small molecule contaminants analysis: A mini-review","volume":"339","author":"Zhao","year":"2021","journal-title":"Food Chem."},{"key":"10.1016\/j.ymthe.2026.08.047_bib140","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.1038\/s41467-020-17837-7","article-title":"Development of light-responsive protein binding in the monobody non-immunoglobulin scaffold","volume":"11","author":"Carrasco-L\u00f3pez","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.08.047_bib141","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41392-023-01589-z","article-title":"Recent advances in targeting the \u201cundruggable\u201d proteins: from drug discovery to clinical trials","volume":"8","author":"Xie","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ymthe.2026.08.047_bib142","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1073\/pnas.1909973116","article-title":"An inhibitor of complement C5 provides structural insights into activation","volume":"117","author":"Reichhardt","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2026.08.047_bib143","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0161-5890(02)00212-2","article-title":"Compstatin, a peptide inhibitor of complement, exhibits species-specific binding to complement component C3","volume":"39","author":"Sahu","year":"2003","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.ymthe.2026.08.047_bib144","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1080\/14756366.2020.1758690","article-title":"A nanobody-derived mimotope against VEGF inhibits cancer angiogenesis","volume":"35","author":"Karami","year":"2020","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.ymthe.2026.08.047_bib145","series-title":"Patients with Advanced Melanoma","article-title":"Pharmacodynamic and Pharmacokinetic Activity of CX-801, a Masked IFN\u03b12b PROBODY\u00ae Cytokine","author":"Povinelli","year":"2025"},{"key":"10.1016\/j.ymthe.2026.08.047_bib146","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.ejca.2006.01.004","article-title":"Inflammation, proteases and cancer","volume":"42","author":"van Kempen","year":"2006","journal-title":"Eur. J. Cancer"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626007732?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626007732?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:58:22Z","timestamp":1790740702000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001626007732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":146,"alternative-id":["S1525001626007732"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.08.047","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Protein-based masks to unlock conditional activation of therapeutics","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.08.047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}